| Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 17845540 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND/AIMS: Chronic hepatitis C (HCV) patients who have failed previous treatment have low sustained viral response (SVR) rates with repeat treatment. We evaluated whether interferon (IFN) induction during retreatment improves response rates. METHODS: Two randomized, controlled trials were conducted in chronic HCV patients who failed IFN. In Study 1, patients received IFN 3 MU daily plus ribavirin (RBV) 1000 mg/day for 4 weeks, followed by IFN 3 MU TIW plus RBV 1000 mg/day for 44 weeks (induction; n=232), or IFN 3 MU TIW plus RBV 1000 mg/day for 48 weeks (non-induction; n=237). In Study 2, patients received IFN 5 MU B.I.D. plus RBV 1000-1200 mg/day for 2 weeks, followed by pegylated IFN (PEG-IFN) 75-150 mug weekly plus RBV 1000-1200 mg/day for 46 weeks (induction; n=201), or PEG-IFN 75-150 mug weekly plus RBV 1000-1200 mg/day for 48 weeks (non-induction; n=206). The primary end point for both trials was SVR. RESULTS: Induction did not increase SVR compared with non-induction, but did increase the on-treatment response among genotype non-1 patients in Study 2. By intention-to-treat (ITT) analysis, SVR in Study 1 was 13% for induction vs. 9% for non-induction (P=NS). In Study 2 (ITT), SVR was 20% for induction vs. 24% for non-induction (P=NS). However, by non-ITT analysis of Study 2, genotype non-1-previous non-responders showed significantly higher response rates with induction than non-induction. CONCLUSION: For chronic HCV patients who have failed IFN, induction with retreatment does not improve SVR, but may be beneficial for patients with genotype non-1 HCV. |
| | |
Authors:
|
Catherine Carr; F Blaine Hollinger; Boris Yoffe; Adil Wakil; Jason Phillips; Natalie Bzowej; Janet Leung; Katherine Mirro; Fred Poordad; Dan H Moore; Robert G Gish |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 27 ISSN: 1478-3223 ISO Abbreviation: Liver Int. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-09-11 Completed Date: 2007-12-20 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: England |
Other Details:
|
Languages: eng Pagination: 1111-8 Citation Subset: IM |
Affiliation:
|
Departments of Medicine and Transplantation, California Pacific Medical Center, San Francisco, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antiviral Agents / adverse effects, therapeutic use* DNA, Viral / analysis Drug Therapy, Combination Female Genotype Hepacivirus / genetics Hepatitis C, Chronic / drug therapy*, ethnology, genetics, pathology Humans Interferon Alfa-2b / adverse effects, therapeutic use* Interferons / adverse effects, therapeutic use* Liver / drug effects, pathology, virology Male Middle Aged Patient Selection Polyethylene Glycols RNA, Viral / blood Ribavirin / adverse effects, therapeutic use* Sex Factors Time Factors Treatment Failure United States Viral Load |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/DNA, Viral; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 9008-11-1/Interferons; 99210-65-8/Interferon Alfa-2b |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and res...
Next Document: Health-related quality of life in patients with chronic hepatitis B.